Faruk Orge

Dr. Faruk Orge


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
XGXiaoming Gong
Xiaoming Gong
FOFaruk Orge
Faruk Orge
Ocular diseases, including glaucoma, diabetic retinopathy (DR), and age-related macular degeneration (AMD), remain major global causes of irreversible vision loss. Despite advances in clinical management, current therapies insufficiently address the shared metabolic, inflammatory, vascular, and neurodegenerative mechanisms underlying these conditions. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for type 2 diabetes and obesity, have emerged as multi-target candidates for ocular therapeutics due to their pleiotropic anti-inflammatory, antioxidant, vasculoprotective, and neuroprotective properties. Preclinical studies consistently demonstrate that GLP-1RAs preserve blood–retina barrier integrity, suppress pathological angiogenesis, mitigate oxidative and inflammatory stress, and protect retinal neurons from degeneration. Complementary clinical and real-world evidence shows a robust and reproducible reduction in glaucoma risk among GLP-1RA users across diabetic and non-diabetic populations. By contrast, findings for DR and AMD are more heterogeneous and appear context-dependent, with potential benefits most evident in early or non-exudative disease stages. Emerging safety considerations—including reports of nonarteritic anterior ischemic optic neuropathy and early DR worsening in the setting of rapid glycemic improvement—highlight the need for careful interpretation, individualized risk assessment, and appropriate ophthalmic monitoring. This review synthesizes molecular mechanisms, experimental data, clinical and pharmacoepidemiologic evidence, and safety signals to critically evaluate the therapeutic potential of GLP-1RAs in ocular disease. We also outline key translational challenges, including the need for ocular-targeted delivery strategies, prospective ophthalmology-specific trials, and precision-medicine approaches to determine when and how GLP-1RAs can be safely advanced as disease-modifying treatments in ophthalmology.

12 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
XGXiaoming Gong
Xiaoming Gong
FOFaruk Orge
Faruk Orge
Ocular diseases – including glaucoma, diabetic retinopathy, and age-related macular degeneration – remain major global causes of irreversible vision loss. Despite therapeutic advances, current interventions that address the convergent metabolic, inflammatory, vascular and neurodegenerative components of these diseases are limited. Glucagon‑like peptide‑1 receptor agonists (GLP‑1RAs), widely used for type 2 diabetes and obesity, have emerged as multi-target candidates for ocular therapeutics due to their pleiotropic anti‑inflammatory, antioxidant, vasculoprotective, and neuroprotective properties. Increasing preclinical and clinical evidence indicates that GLP‑1RAs preserve blood–retina barrier integrity, inhibit pathological angiogenesis, reduce inflammation, promote antioxidant responses and protect retinal neurons from degeneration. However, rare ocular adverse events – including nonarteritic anterior ischemic optic neuropathy and “early worsening” of diabetic retinopathy – highlight the need for a balanced and comprehensive consideration of evidence. This review synthesizes mechanistic in-sights, experimental findings, clinical data, and safety considerations to critically assess the potential of GLP‑1RAs as disease‑modifying therapeutics for ocular disorders and outlines translational challenges and research priorities to guide future ophthalmology‑focused investigations.